Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation
Journal of Biochemical and Molecular Toxicology · 2023-05 · 37 (5)
DOI: 10.1002/jbt.23313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 22.01.2023. Verfasst von Wei Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Ganzhou People's Hospital, Jiangxi, Ganzhou, China. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinase, Colonic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
This study investigated that dieckol (DKL), a natural drug, inhibits colon cancer cell proliferation and migration by inhibiting phosphoinositide‐3‐kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) phosphorylation in HCT‐116 cells. The cells were treated with DKL in various concentrations (32 and 50 μM) for 24 h and then analyzed for various experiments. MTT (tetrazolium bromide) and crystal violet assay investigated DKL‐mediated cytotoxicity. Dichlorodihydrofluorescein diacetate staining was used to assess the reactive oxygen species (ROS) measurement, and apoptotic changes were studied by dual acridine orange and ethidium bromide staining. Protein expression of cell survival, cell cycle, proliferation, and apoptosis protein was evaluated by western blot analysis. Results indicated that DKL produces significant cytotoxicity in HCT‐116, and the half‐maximal inhibitory concentration was found to be 32 μM for 24‐h incubation. Moreover, effective production of ROS and enhanced apoptotic signs were observed upon DKL treatment in HCT‐116. DKL induces the expression of phosphorylated PI3K, AKT, and mToR‐associated enhanced expression of cyclin‐D1, proliferating cell nuclear antigen, cyclin‐dependent kinase (CDK)‐4, CDK‐6, and Bcl‐2 in HCT‐116. In addition, proapoptotic proteins such as Bax, caspase‐9, and caspase‐3 were significantly enhanced by DKL treatment in HCT‐116. Hence, DKL has been considered a chemotherapeutic drug by impeding the expression of PI3K‐, AKT‐, and mTOR‐mediated inhibition of proliferation and cell cycle‐regulating proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Ganzhou People's Hospital, Jiangxi, Ganzhou, China.
- Department of Clinical Laboratory, Shandong Provincial Third Hospital, Jinan, Shandong, China.
- Department of Oncology, The First Hospital of Yulin, Shaanxi, Yulin, China.
- Department of Gastroenterology, Hongze District People's Hospital, Jiangsu, Huai'an, China.
Zitieren
APA
Dai, W., Dai, Y. G., Ren, D. F., & Zhu, D. W. (2023). Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. Journal of Biochemical and Molecular Toxicology, 37(5). https://doi.org/10.1002/jbt.23313
Vancouver
Dai W, Dai YG, Ren DF, Zhu DW. Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. Journal of Biochemical and Molecular Toxicology. 2023;37(5). doi:10.1002/jbt.23313
BibTeX
@article{Dai2023,
author = {Dai, Wei and Dai, Yong Gang and Ren, Dong Feng and Zhu, Da Wei},
title = {Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
volume = {37},
number = {5},
doi = {10.1002/jbt.23313}
}
EUVIMED